These findings implicate PTPRH as a potent modulator of glycolysis and tumor aggressiveness via PI3K/AKT/mTOR activation, reinforcing its value as a therapeutic target in NSCLC. Here, PIK3CA is linked to non-small cell lung carcinoma.